Abstract:Objective:Th2 cell and cytokine IL-10 play an important role in the pathogenesis of membranous lupus nephropathy. Tacrolimus (FK506), an inhibitor of calcineurin, can inhibit the synthesis of IL-10 potently. In this study, we investigated the efficacy and adverse effects of tacrolimus in patients with membranous lupus nephropathy (WHO classification, class Ⅴ lupus nephritis). Methodology:A prospective preliminary study was conducted in 11 patients with membranous lupus nephritis proven by renal biopsy. In all the patients, the daily excretion of urinary protein exceeded 2.0 g, and the serum creatinine (SCr) was less than up-lower limit of normal range (110 μmol/L). All the patients received a regimen of FK506 combined with steroids. The starting dosage of FK506 was 0.1 mg/(kg·d), combined with prednisone at 0.6 mg/(kg·d). The dosage of prednisone was tapered after 4 weeks until a maintenance dosage of 10mg/d. Complete remission (CR) referred to daily urinary protein excretion reduced to 0.4g or below,no active urinary sediment (urinary RBC10×10 4/ml, no cast nor urinary WBC), serum albumin over 35g/L, SCr in normal range, and negativity of serum anti-dsDNA antibody. Partial remission (PR) referred to daily urinary protein excretion reduced to a range of 0.4-2.0 g and the reduction exceeded 50% or more of the baseline level, serum albumin equal or more than 30g/L, and SCr level in normal range. No-response (NR) referred to daily urinary protein excretion still exceeded 2.0g or the reduction less than 50% of the baseline value, serum albumin below 30g/L, or increment of SCr to more than 50% of the baseline value, or transformation to Class Ⅳ LN in repeat renal biopsy. Results:All the patients tolerated well to the regimen of FK506 for 3-15months, with nobody withdrew from the study. After treatment for 3 months, 2 of the 11 patients (18.2%) achieved complete remission, 5 patients (45.5%) achieved partial remission. In the 10 patients treated with FK506 for more than 6 months, 4 patients (40%) got CR and 4 patients got PR (40%) respectively. The median time to achieve CR/PR was 3 months (1-7months). In 7 of the 10 patients with hypoalbuminemia, serum albumin increased to normal range after treatment for 3 months. The titer of serum ANA and anti-dsDNA decreased,and the level of serum complement component increased significantly after treatment. Repeated renal biopsy in 8 patients (3 patients with CR, 3 with PR and 2 with NR) demonstrated that the activity index decreased from 4.8±2.38 to 2.25±1.28 (p0.05). There was no significant exacerbation of interstitial fibrosis. The adverse effects included temporary increased SCr level in 6 patients, and diarrhea, hypertension, herpes zoster each in 1 patient respectively. Conclusion:This preliminary study demonstrated that the regime of FK506 combined with low-dose prednisone is effective for patients with membranous lupus nephropathy.

The Effect of FK506 on the Early Experimental Membranous Nephropathy Rats

Therapeutic Effects of FK506 on IgA Nephropathy Rat

Mycophenolate mofetil and FK506 have different effects on kidney allograft fibrosis in rats that underwent chronic allograft nephropathy

Effect of Kaempferol on Tacrolimus-Induced Nephrotoxicity and Calcineurin B1 Expression Level in Animal Model

Effect of Switch from Cyclosporine to FK506 on Renal Graft Outcome in Patients after Initial Acute Rejection

Clinical Study on the Use of FK506 after Renal Transplantation

FK506 ameliorates renal injury in early experimental diabetic rats induced by streptozotocin

Clinical Application of FK506 in Renal Transplantation

FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats

Long-term Evaluation of FK506 Based Immunosuppressive Therapy in Kidney Transplantation

Comparison of Expression of TGF-β1, its Receptors TGFβ1R-I and TGFβ1R-II in Rat Kidneys During Chronic Nephropathy Induced by Cyclosporine and Tacrolimus

Electrospun Polymer Fibers Modified with FK506 for the Long-Term Treatment of Acute Cardiac Allograft Rejection in a Heart Transplantation Model.

Clinical effect of FK506 on the treatment of steroid-resistant rejection after kidney transplantation

The Comparison of Two Immunosuppression Schemes Containing Tacrolimus in Renal Transplant Recipients

Acute Influence of FK506 on T-Lymphocyte Populations of Peripheral Blood and Spleen in Rats

A Prospective Preliminary Study of Tacrolimus (FK506) Combined with Low-Dose Prednisone in Patients with Membranous Lupus Nephropathy

FK506 Reduces Liver Ischemia-Reperfusion Injury in a Rat Model of Autologous Orthotopic Liver Transplantation by Decreasing HMGB1 Release

The Experimental Study of the Effect of Mycophenolate Mofetil on Nephrotic Syndrome in Rats

Therapeutical Effect of Mycophenolate Mofetil in Rats with Immune Complex Glomerulonephritis

Pre-treatment with FK506 Reduces Hepatic Ischemia-Reperfusion Injury in Rats.

Protective Effect of FK506 on Myocardial Ischemia/Reperfusion Injury by Suppression of CaN and ASK1 Signaling Circuitry